Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: Identifying targets for COPD treatment through gene expression analyses

doi:

Figure Lengend Snippet: Summary of gene expression profiling studies involving human COPD/emphysema samples

Article Snippet: COPD GOLD2 vs. GOLD0 , Whole lung , Incyte Unigem high-density microarray (10,000 transcripts) SAGE (59,000 tags) , Apoptosis-related genes Inflammation-related genes Transcription factors (increased) Collagens (decreased) , Egr-1/Fos CTGF, CYR61, CX3CL1, TGFB1, and PDGFRA , .

Techniques: Expressing, Functional Assay, Microarray

Journal: The Journal of Clinical Investigation

Article Title: Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition

doi: 10.1172/JCI37691

Figure Lengend Snippet: (A) Breast tumor tissue microarrays were subjected to immunohistochemistry using antibodies against Six1 and cyclin D1. They were then scored for staining intensity on a 0–4 scale. Representative examples are shown of tumor cores with low-intensity Six1 staining ([scored 0–1], core number AA6), medium-intensity Six1 staining ([scored 1.5–2.5], core number DB6), and high-intensity Six1 staining ([scored 3–4], core number DB8), with their corresponding intensity of cyclin D1 staining (original magnification, ×40). (B) The intensity of cyclin D1 staining increases with increasing intensity of Six1 staining, as scored on a 0–4 scale. Six1 staining intensity groups were established as described in A. Error bars represent mean ± SEM.

Article Snippet: High-density breast cancer tissue microarrays were obtained from Biomax (BR1921), and immunohistochemistry was performed using the protocols detailed above for Six1 (Atlas Antibodies) and cyclin D1 (Thermo Scientific).

Techniques: Immunohistochemistry, Staining

Journal: BMC Cancer

Article Title: RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation

doi: 10.1186/s12885-017-3908-y

Figure Lengend Snippet: RCC2 was over-expressed in lung cancers and ovarian cancers. a IHC of HeLa cells was performed with anti-RCC2 antibody (D14F3, cell signaling). RCC2 signals were seen in nucleus and midbody of a telophase cell as expected. Cytoplasmic RCC2 was also observed. b RCC2 expression in a lung cancer tissue microarray was evaluated by IHC. RCC2 were not seen in normal lung (left) but highly expressed in lung cancer (10×, scale bar: 100 μm). In addition to nuclei, RCC2 signals were also seen in cytoplasm in some lung cancers ( c ). d RCC2 expression in an ovarian cancer tissue microarray was evaluated by IHC. Normal ovaries expressed none or weak RCC2 (−~+) (left). Increased RCC2 expression was seen in majority of ovarian cancers

Article Snippet: Lung carcinoma progression tissue microarray (LC2083; Biomax; Rockville, MD, USA) and ovarian cancer and normal tissue high density tissue microarray (OV208; Biomax) were de-paraffinized in xylene, antigen-retrieved by heating in 0.01 M sodium citrate buffer (pH 6.0) at 95 °C for 10 min, blocked in 10% normal goat serum for 30 min and incubated with an anti-RCC2 antibody (D14F3; Cell Signaling, Danvers, MA, USA) overnight at 4 °C.

Techniques: Expressing, Microarray

Journal: Cancers

Article Title: Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management

doi: 10.3390/cancers15102746

Figure Lengend Snippet: Available gene expression assays predictive of prognosis in early-stage CRC.

Article Snippet: ColoPrint colon cancer recurrence assay , Agendia, Inc. , 18-gene expression profile , Fresh tissue or fresh, frozen tissue , Agendia customized whole-genome high-density microarrays , Not FDA approved , [ , , ] .

Techniques: Gene Expression, Expressing, Formalin-fixed Paraffin-Embedded, Amplification, Microarray, Derivative Assay